

# Delivering Solutions for Nucleic Acid Therapeutics

Two Locations. One Approach. One Agilent.

## Building on our success

- State of the art equipment trains
- World class analytical services
- Consistent approach to process development and scale-up



Boulder, Colorado



Frederick, Colorado

Agilent's Boulder, Colorado manufacturing site is a U.S. Food & Drug Administration (FDA) inspected facility and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) accredited foreign manufacturer for non-sterile drugs.

[www.agilent.com/chem/nucleicacid](http://www.agilent.com/chem/nucleicacid)  
[pdl-boulderinfo@agilent.com](mailto:pdl-boulderinfo@agilent.com)

This information is subject to change without notice.

© Agilent Technologies, Inc. 2019  
Published in the USA, April, 2019  
5991-9355EN

Partner with Agilent's Nucleic Acid Solutions Division and benefit from industry leading experience to efficiently advance your lead oligo candidates from clinic to market with a common goal of patient health and safety.

## Manufacturing late stage and commercial quantities

Agilent Technologies has acquired a 20 acre plot in Frederick, Colorado. Construction of the new pharmaceutical facility was completed in 2018 and cGMP operations will commence in 2019.

The expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid based therapeutics.

## Continuing to break new ground in nucleic acid therapeutics manufacturing

When your next clinical trial or patient's well being depends on API availability, security of supply is a top priority.

Put your trust in Agilent to meet your clinical and commercial needs.

